Which has stronger earnings and valuation, CRMD or HCM?

HUTCHMED has higher revenue and earnings than CorMedix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CorMedix $457.20M 1.32 $163.05M $2.14 3.61 HUTCHMED $548.51M 4.36 $456.91M N/A N/A

Is CRMD or HCM more profitable?

CorMedix has a net margin of 40.49% compared to HUTCHMED's net margin of 0.00%. CorMedix's return on equity of 40.52% beat HUTCHMED's return on equity. Company Net Margins Return on Equity Return on Assets CorMedix 40.49% 40.52% 20.61% HUTCHMED N/A N/A N/A

CorMedix (CRMD) Competitors

$7.72 -0.07 (-0.90%)

Closing price 04:00 PM Eastern

Extended Trading

$7.75 +0.03 (+0.39%)

As of 04:47 PM Eastern

Compare

CRMD vs. SUPN, HRMY, OCUL, TRVI, and HCM

Should you buy CorMedix stock or one of its competitors? CorMedix's main competitors and comparable companies include Supernus Pharmaceuticals (SUPN), Harmony Biosciences (HRMY), Ocular Therapeutix (OCUL), Trevi Therapeutics (TRVI), and HUTCHMED (HCM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does CorMedix compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and CorMedix (NASDAQ:CRMD) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership and analyst recommendations.

CorMedix has a net margin of 40.49% compared to Supernus Pharmaceuticals' net margin of -13.23%. CorMedix's return on equity of 40.52% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
CorMedix	40.49%	40.52%	20.61%

Supernus Pharmaceuticals currently has a consensus price target of $62.83, suggesting a potential upside of 49.67%. CorMedix has a consensus price target of $15.00, suggesting a potential upside of 93.97%. Given CorMedix's stronger consensus rating and higher probable upside, analysts plainly believe CorMedix is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75

In the previous week, Supernus Pharmaceuticals had 3 more articles in the media than CorMedix. MarketBeat recorded 3 mentions for Supernus Pharmaceuticals and 0 mentions for CorMedix. Supernus Pharmaceuticals' average media sentiment score of 0.96 beat CorMedix's score of 0.94 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Supernus Pharmaceuticals	Positive
CorMedix	Positive

CorMedix has lower revenue, but higher earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.40	-$38.55M	-$1.92	N/A
CorMedix	$457.20M	1.32	$163.05M	$2.14	3.61

Supernus Pharmaceuticals has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, CorMedix has a beta of 1.5, suggesting that its stock price is 50% more volatile than the broader market.

34.2% of CorMedix shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 3.5% of CorMedix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

CorMedix beats Supernus Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does CorMedix compare to Harmony Biosciences?

CorMedix (NASDAQ:CRMD) and Harmony Biosciences (NASDAQ:HRMY) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

CorMedix has higher earnings, but lower revenue than Harmony Biosciences. CorMedix is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$457.20M	1.32	$163.05M	$2.14	3.61
Harmony Biosciences	$959.90M	2.55	$158.69M	$3.08	13.66

CorMedix has a net margin of 40.49% compared to Harmony Biosciences' net margin of 18.88%. CorMedix's return on equity of 40.52% beat Harmony Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
Harmony Biosciences	18.88%	20.06%	14.15%

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are owned by institutional investors. 3.5% of CorMedix shares are owned by company insiders. Comparatively, 11.0% of Harmony Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Harmony Biosciences had 5 more articles in the media than CorMedix. MarketBeat recorded 5 mentions for Harmony Biosciences and 0 mentions for CorMedix. Harmony Biosciences' average media sentiment score of 1.58 beat CorMedix's score of 0.94 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
CorMedix	Positive
Harmony Biosciences	Very Positive

CorMedix currently has a consensus price target of $15.00, indicating a potential upside of 93.97%. Harmony Biosciences has a consensus price target of $47.11, indicating a potential upside of 11.97%. Given CorMedix's stronger consensus rating and higher possible upside, equities research analysts clearly believe CorMedix is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Harmony Biosciences	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

CorMedix has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market.

Summary

CorMedix and Harmony Biosciences tied by winning 8 of the 16 factors compared between the two stocks.

How does CorMedix compare to Ocular Therapeutix?

CorMedix (NASDAQ:CRMD) and Ocular Therapeutix (NASDAQ:OCUL) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, earnings and risk.

CorMedix has a net margin of 40.49% compared to Ocular Therapeutix's net margin of -579.10%. CorMedix's return on equity of 40.52% beat Ocular Therapeutix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
Ocular Therapeutix	-579.10%	-59.89%	-45.99%

In the previous week, Ocular Therapeutix had 12 more articles in the media than CorMedix. MarketBeat recorded 12 mentions for Ocular Therapeutix and 0 mentions for CorMedix. CorMedix's average media sentiment score of 0.94 beat Ocular Therapeutix's score of 0.67 indicating that CorMedix is being referred to more favorably in the media.

Company	Overall Sentiment
CorMedix	Positive
Ocular Therapeutix	Positive

CorMedix has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, Ocular Therapeutix has a beta of 0.97, meaning that its share price is 3% less volatile than the broader market.

CorMedix has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$457.20M	1.32	$163.05M	$2.14	3.61
Ocular Therapeutix	$51.95M	42.27	-$265.94M	-$1.42	N/A

CorMedix currently has a consensus price target of $15.00, indicating a potential upside of 93.97%. Ocular Therapeutix has a consensus price target of $25.75, indicating a potential upside of 157.55%. Given Ocular Therapeutix's stronger consensus rating and higher possible upside, analysts clearly believe Ocular Therapeutix is more favorable than CorMedix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Ocular Therapeutix	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.77

34.2% of CorMedix shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 3.5% of CorMedix shares are held by insiders. Comparatively, 3.1% of Ocular Therapeutix shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

CorMedix beats Ocular Therapeutix on 10 of the 16 factors compared between the two stocks.

How does CorMedix compare to Trevi Therapeutics?

CorMedix (NASDAQ:CRMD) and Trevi Therapeutics (NASDAQ:TRVI) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

CorMedix has a net margin of 40.49% compared to Trevi Therapeutics' net margin of 0.00%. CorMedix's return on equity of 40.52% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
Trevi Therapeutics	N/A	-23.59%	-22.64%

In the previous week, Trevi Therapeutics had 6 more articles in the media than CorMedix. MarketBeat recorded 6 mentions for Trevi Therapeutics and 0 mentions for CorMedix. CorMedix's average media sentiment score of 0.94 beat Trevi Therapeutics' score of 0.92 indicating that CorMedix is being referred to more favorably in the media.

Company	Overall Sentiment
CorMedix	Positive
Trevi Therapeutics	Positive

CorMedix presently has a consensus price target of $15.00, indicating a potential upside of 93.97%. Trevi Therapeutics has a consensus price target of $27.08, indicating a potential upside of 81.05%. Given CorMedix's higher possible upside, analysts clearly believe CorMedix is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

CorMedix has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$457.20M	1.32	$163.05M	$2.14	3.61
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 3.5% of CorMedix shares are owned by insiders. Comparatively, 15.4% of Trevi Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CorMedix has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market.

Summary

CorMedix beats Trevi Therapeutics on 10 of the 16 factors compared between the two stocks.

How does CorMedix compare to HUTCHMED?

CorMedix (NASDAQ:CRMD) and HUTCHMED (NASDAQ:HCM) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

CorMedix currently has a consensus target price of $15.00, indicating a potential upside of 93.97%. HUTCHMED has a consensus target price of $14.87, indicating a potential upside of 8.44%. Given CorMedix's stronger consensus rating and higher probable upside, research analysts plainly believe CorMedix is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CorMedix	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
HUTCHMED	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.43

34.2% of CorMedix shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 3.5% of CorMedix shares are owned by company insiders. Comparatively, 3.6% of HUTCHMED shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

CorMedix has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

CorMedix has a net margin of 40.49% compared to HUTCHMED's net margin of 0.00%. CorMedix's return on equity of 40.52% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CorMedix	40.49%	40.52%	20.61%
HUTCHMED	N/A	N/A	N/A

In the previous week, HUTCHMED had 2 more articles in the media than CorMedix. MarketBeat recorded 2 mentions for HUTCHMED and 0 mentions for CorMedix. HUTCHMED's average media sentiment score of 1.03 beat CorMedix's score of 0.94 indicating that HUTCHMED is being referred to more favorably in the news media.

Company	Overall Sentiment
CorMedix	Positive
HUTCHMED	Positive

HUTCHMED has higher revenue and earnings than CorMedix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CorMedix	$457.20M	1.32	$163.05M	$2.14	3.61
HUTCHMED	$548.51M	4.36	$456.91M	N/A	N/A

Summary

CorMedix beats HUTCHMED on 8 of the 15 factors compared between the two stocks.

Get CorMedix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CRMD vs. The Competition

Export

Metric	CorMedix	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$602.74M	$12.42B	$7.20B	$13.72B
Dividend Yield	N/A	2.64%	2.57%	12.64%
P/E Ratio	3.61	797.25	274.71	25.48
Price / Sales	1.32	800.36	683.53	100.81
Price / Cash	3.82	87.33	77.01	51.20
Price / Book	1.50	10.51	10.46	6.33
Net Income	$163.05M	$2.81B	$3.48B	$358.24M
7 Day Performance	-1.11%	2.84%	0.93%	1.28%
1 Month Performance	-5.35%	3.37%	0.08%	-1.98%
1 Year Performance	-33.85%	3.58%	18.35%	5.40%

CorMedix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CRMD CorMedix	2.9815 of 5 stars	$7.72 -0.9%	$15.00 +94.3%	-29.9%	$601.73M	$457.20M	3.61	191
SUPN Supernus Pharmaceuticals	3.561 of 5 stars	$41.49 -0.4%	$62.83 +51.4%	-4.2%	$2.42B	$718.95M	N/A	778
HRMY Harmony Biosciences	3.7395 of 5 stars	$41.54 +0.0%	$47.11 +13.4%	+33.3%	$2.42B	$868.45M	13.48	293	Positive News
OCUL Ocular Therapeutix	3.2272 of 5 stars	$10.72 +2.2%	$25.75 +140.2%	-16.6%	$2.30B	$51.95M	N/A	325	Positive News Analyst Forecast
TRVI Trevi Therapeutics	3.7578 of 5 stars	$15.89 -0.1%	$27.08 +70.4%	+90.6%	$2.27B	N/A	N/A	34	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CRMD) was last updated on 9/18/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CorMedix (CRMD) Competitors

CRMD vs. SUPN, HRMY, OCUL, TRVI, and HCM

How does CorMedix compare to Supernus Pharmaceuticals?

Summary

How does CorMedix compare to Harmony Biosciences?

Summary

How does CorMedix compare to Ocular Therapeutix?

Summary

How does CorMedix compare to Trevi Therapeutics?

Summary

How does CorMedix compare to HUTCHMED?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD vs. The Competition

CorMedix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CorMedix (CRMD) Competitors

CRMD vs. SUPN, HRMY, OCUL, TRVI, and HCM

How does CorMedix compare to Supernus Pharmaceuticals?

Is SUPN or CRMD more profitable?

Do analysts prefer SUPN or CRMD?

Does the media prefer SUPN or CRMD?

Which has better earnings and valuation, SUPN or CRMD?

Which has more risk & volatility, SUPN or CRMD?

Do institutionals & insiders hold more shares of SUPN or CRMD?

Summary

How does CorMedix compare to Harmony Biosciences?

Which has better valuation & earnings, CRMD or HRMY?

Is CRMD or HRMY more profitable?

Do institutionals & insiders have more ownership in CRMD or HRMY?

Does the media favor CRMD or HRMY?

Do analysts recommend CRMD or HRMY?

Which has more volatility & risk, CRMD or HRMY?

Summary

How does CorMedix compare to Ocular Therapeutix?

Is CRMD or OCUL more profitable?

Does the media prefer CRMD or OCUL?

Which has more volatility and risk, CRMD or OCUL?

Which has stronger valuation & earnings, CRMD or OCUL?

Do analysts recommend CRMD or OCUL?

Do institutionals and insiders believe in CRMD or OCUL?

Summary

How does CorMedix compare to Trevi Therapeutics?

Is CRMD or TRVI more profitable?

Does the media favor CRMD or TRVI?

Do analysts rate CRMD or TRVI?

Which has preferable earnings and valuation, CRMD or TRVI?

Do insiders & institutionals have more ownership in CRMD or TRVI?

Which has more risk & volatility, CRMD or TRVI?

Summary

How does CorMedix compare to HUTCHMED?

Do analysts prefer CRMD or HCM?

Do institutionals and insiders believe in CRMD or HCM?

Which has more risk and volatility, CRMD or HCM?

Is CRMD or HCM more profitable?

Does the media prefer CRMD or HCM?

Which has stronger earnings and valuation, CRMD or HCM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRMD vs. The Competition

CorMedix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools